Mounjaro Manufacturer Copay Program: How to Cut Your Cost in 2026

What the Mounjaro Copay Savings Card Actually Covers

The Eli Lilly Mounjaro Savings Card is a manufacturer-funded program designed to lower the patient copay on brand-name tirzepatide for people who carry qualifying commercial health insurance. If your plan already covers Mounjaro, this card can bring your monthly out-of-pocket to $25 or less per fill, depending on the specific terms active at the time you enroll.

The card works by paying the difference between your insurer's required copay or coinsurance and the program floor price. So if your plan charges a $150 specialty-tier copay, the savings card covers approximately $125 of that amount. The card does not replace insurance. It supplements it. Lilly periodically adjusts maximum annual benefit caps and per-fill limits, so the exact savings fluctuate. One version of the program capped total annual benefits at $3,400; subsequent iterations have raised or restructured that ceiling. The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 20.9% mean body weight reduction at 72 weeks versus 3.1% with placebo, a result that has driven massive demand and put persistent pressure on both supply and pricing [1]. That efficacy profile explains why Lilly has maintained aggressive copay support. They want eligible patients to start and stay on therapy.

You should verify current terms directly through the Lilly Mounjaro savings portal or by calling the number on your existing card before each refill cycle.

Who Qualifies (and Who Doesn't)

Eligibility is straightforward but strict. You must be a U.S. resident age 18 or older, hold a valid prescription for brand-name Mounjaro, and carry commercial health insurance that covers at least part of the drug's cost. The card is activated per patient, not per household.

The exclusions matter more than the inclusions. If you receive drug benefits through Medicare Part D, Medicaid, Medigap, the VA, TRICARE, or any other federal or state-funded healthcare program, you are ineligible. This is not a Lilly-specific restriction. The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) prohibits manufacturer copay assistance for federally funded beneficiaries [2]. That single rule eliminates roughly 65 million Medicare Part D enrollees from participation, per CMS enrollment data from 2025.

Patients whose commercial plans refuse to cover Mounjaro at all (a prior authorization denial, for instance) also face complications. The savings card typically requires an adjudicated pharmacy claim with at least partial plan payment. If your insurer rejects coverage outright, the card may not activate. Some patients have reported success using the card at specific pharmacies that run a secondary billing pass, but this is pharmacy-dependent and not guaranteed.

How to Activate the Savings Card: Step by Step

Getting the card set up takes about 10 minutes. The process has not changed dramatically since the program launched, though Lilly has shifted portions of it online.

First, visit the official Mounjaro savings page on Lilly's website. You will answer a short eligibility screener confirming your insurance type, age, and residency. If you pass, the system generates a digital savings card with a BIN, PCN, Group number, and Member ID. You can print it, screenshot it, or save it to a phone wallet app.

Next, present the card to your pharmacy at fill time along with your regular insurance card. The pharmacist runs your insurance claim first, then applies the savings card as a secondary payer. The two-step adjudication process is what produces the reduced copay.

A few practical notes. Not every pharmacy's system handles secondary manufacturer cards smoothly. Large chains (CVS, Walgreens, Walmart) generally process them without difficulty. Independent pharmacies sometimes need to call the card's help line to troubleshoot BIN routing. If your first fill attempt fails, ask the pharmacist to manually enter the BIN and PCN rather than scanning the card. According to a 2023 IQVIA analysis, manufacturer copay cards were used on approximately 16% of all branded specialty drug fills in the U.S. [3]. Pharmacists are familiar with the workflow.

What Happens When Your Insurance Denies Mounjaro

Insurance denials are common with GLP-1 receptor agonist/GIP receptor agonist therapies. Many commercial plans have placed tirzepatide on specialty tiers with prior authorization requirements, step therapy protocols, or outright exclusions for weight management indications. A 2024 KFF employer survey found that 45% of large employers imposed prior authorization on GLP-1 medications, and 25% excluded them from formularies entirely for obesity [4].

If your plan denies coverage, you have three immediate options. The first is appealing the denial. Your prescriber's office submits clinical documentation supporting medical necessity. For type 2 diabetes indications, appeals succeed at higher rates because tirzepatide has full FDA approval for that condition. The SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.58% versus 1.86% for semaglutide 1 mg at 40 weeks, giving prescribers strong comparative data for appeal letters [5].

The second option is asking your prescriber to pursue a formulary exception or tier reduction request. This does not change the denial but can move Mounjaro to a lower cost-sharing tier if your plan's pharmacy and therapeutics committee agrees.

The third option is Lilly's separate patient assistance program for uninsured or underinsured patients. This is distinct from the copay card and is income-based. Eligibility thresholds vary, but patients at or below 400% of the federal poverty level ($62,400 for an individual in 2026) may qualify for free or heavily discounted drug supply shipped directly from Lilly's fulfillment partner.

Cash Price vs. Copay Card vs. Compounded Tirzepatide

The cost differences across channels are large enough to change treatment decisions. A direct comparison helps.

Paying full cash price for brand-name Mounjaro at a retail pharmacy averages $1,023 per month in 2026. This number shifts by pharmacy and region, but it has remained within the $950 to $1,100 corridor since launch. Using the manufacturer copay card with qualifying commercial insurance drops that to approximately $25 per fill, assuming your plan adjudicates the claim.

Compounded tirzepatide, available through 503B outsourcing facilities when the FDA shortage designation applies, averages approximately $249 per month. The FDA's drug shortage database listed tirzepatide in shortage status beginning in late 2022 [6]. As of this writing, check the FDA drug shortage page for the current status, because compounding legality is directly tied to that designation. The FDA has taken enforcement actions against compounders selling tirzepatide when shortage conditions were resolved, then reinstated compounding eligibility when shortages recurred.

"The legal status of compounded GLP-1 receptor agonists depends entirely on FDA shortage determinations, which can change with limited advance notice," noted a 2024 FDA guidance document on 503B outsourcing facilities [7].

Patients switching between compounded and brand-name tirzepatide should be aware that compounded versions may use different salt forms, concentrations, or excipients. The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommends FDA-approved formulations as first-line, with compounded alternatives only when access barriers prevent use of the approved product [8].

Stacking Savings: Copay Card Plus Other Discounts

The copay card cannot be combined with government insurance, but it can sometimes stack with other commercial mechanisms. Here is what works and what does not.

Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA) can be used to pay your residual copay after the manufacturer card applies. If your post-card copay is $25, you can pay that $25 from pre-tax HSA/FSA dollars. This is a small but real additional savings of roughly 25-35% on that remaining amount, depending on your marginal tax bracket.

Pharmacy discount cards (GoodRx, RxSaver, etc.) cannot be stacked with the manufacturer copay card at the same transaction. The pharmacy system processes one discount mechanism per claim adjudication. However, you can compare whether the discount card or the copay card produces a lower price and use whichever is cheaper. For most commercially insured patients, the manufacturer card wins.

Some employer plans offer separate copay assistance programs administered through benefits managers like Optum or Express Scripts. These employer-funded programs may or may not coordinate with manufacturer cards. Check with your benefits administrator.

"Patients should ask their pharmacist to run a test claim with the savings card before finalizing, because the effective price depends on how the patient's specific plan adjudicates the primary claim," according to guidance published by the American Pharmacists Association [9].

Medicare and Medicaid Patients: Your Alternatives

Federal program enrollees are locked out of the copay card, but they are not without options. The gap is real, though. Medicare Part D plans that cover Mounjaro for type 2 diabetes may still impose specialty-tier cost-sharing of $100 to $300+ per month, depending on the plan's benefit phase.

The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, fully effective as of 2025, provides a ceiling [10]. Once a Medicare beneficiary hits $2,000 in total Part D out-of-pocket costs across all covered drugs, their cost-sharing drops to $0 for the remainder of the calendar year. For a patient whose only expensive medication is Mounjaro, this means roughly 2 to 3 months of higher copays followed by $0 copays for the rest of the year.

Medicaid coverage for Mounjaro varies by state. Some state Medicaid programs cover tirzepatide for type 2 diabetes but not for obesity. Others require step therapy through metformin and a sulfonylurea before approving GLP-1/GIP agonists. The Kaiser Family Foundation reported in 2024 that only 16 state Medicaid programs covered any GLP-1 receptor agonist for weight management [4].

Lilly's patient assistance program (Lilly Cares) is available to uninsured patients and may also serve Medicare beneficiaries who meet income thresholds and have exhausted other options. The application requires proof of income and a prescriber signature.

How Long the Savings Card Lasts and Renewal Rules

The copay card is not a one-time benefit. It typically renews on a calendar-year basis, resetting the maximum annual benefit each January. However, Lilly has periodically restructured the program's terms, so the renewal mechanics active in 2026 may differ from prior years.

Most patients receive an initial card valid for 24 months from activation, with annual benefit caps resetting at each calendar year boundary. After the initial eligibility period expires, you reapply through the same online portal. Reapplication takes the same 10 minutes as initial activation. There is no waiting period between the end of one eligibility window and the start of a new one.

One catch: if your insurance status changes mid-year (for example, you move from a commercial plan to Medicare at age 65), your copay card becomes invalid immediately. Using the card after losing commercial insurance eligibility is technically benefits fraud. The card's terms of use state that the patient is responsible for confirming continued eligibility at each fill.

Lilly does not currently require re-verification of insurance status at each pharmacy fill. The system relies on the pharmacy's claims adjudication to detect plan type. But if an audit flags a fill that occurred after a coverage transition, the patient may be liable for repayment of the manufacturer subsidy.

Tips for Keeping Mounjaro Costs Low Long-Term

Cost management for tirzepatide is an ongoing process, not a one-time signup. Practical steps that compound savings over time include the following.

Review your employer's formulary annually during open enrollment. Plans reclassify drugs every year. A plan that excluded Mounjaro in 2025 may add it in 2026 after negotiating rebates with Lilly. Ask your HR benefits team for the plan's specialty drug formulary before selecting coverage.

Request 90-day fills when your plan and pharmacy allow them. Many copay cards apply per-fill, not per-day-supply, so a 90-day fill uses one of your annual fill allotments rather than three. This does not always reduce cost, but it can if your plan charges a lower copay for 90-day specialty fills through mail order.

Track the FDA shortage status of tirzepatide if you are considering compounded alternatives. The shortage designation can change quarterly. Bookmark the FDA shortage database and check it before ordering compounded supply [6].

Ask your prescriber about dose optimization. The SURMOUNT-3 trial demonstrated that patients who achieved target weight loss could, under clinical supervision, evaluate whether dose adjustments were appropriate for maintenance phases [11]. Lower maintenance doses directly reduce per-fill cost. A 2.5 mg pen costs less than a 15 mg pen at the same pharmacy.